are widely distributed at the cell surface and in the extracellular matrix. They consist of a protein core to which one or more glycosaminoglycan side chains are covalently attached conferring a strong negative charge on proteoglycans (1, 2). Interactions of proteoglycans with a number of matrix proteins including collagens are important in regulating cell behaviour and fibril formation during development and pathophysiological events. Interactions with collagens can be dependent on the proteoglycan core protein or on the glycosaminoglycans chains. The heparan sulfate chain has various important biological properties and influences cell behavior through interactions with a variety of matrix proteins. Heparin-binding sites have been identified and characterized in a wide range of matrix proteins including collagens, but the structural Collagen V, although a quantitatively minor component of connective tissues plays a crucial role in matrix organization. Several isoforms of collagen V, including hybrid molecules containing collagen XI chains (3), occur in tissues, but the predominant molecular form is the heterotrimer [α1(V)] 2 α2(V), whereas the α1(V)α2(V) α3(V) molecule and the [α1(V)] 3 homotrimer are minor isoforms with a more restricted tissue distribution. Collagen V interacts with proteoglycans, which are widely distributed at the cell surface and in the extracellular matrix. It binds to the two small proteoglycans, decorin and biglycan, to the proteoglycan form of macrophage colony-stimulating factor (4), to the membrane chondroitin sulfate proteoglycan NG2 (5) and to syndecan-1 (6, 7). Binding to collagen V involves either the core protein or the glycosaminoglycan chains. Collagen V was shown to bind heparin (HP) through a 12kDa fragment of the α1(V) chain referred to as HepV. Interestingly, we also showed that the recombinant HepV fragment supports heparin-dependent cell adhesion (8). The binding site for heparin is found in the α1 chain of collagen V, whilst the two other chains of collagen V, α2(V) and α3(V), do not bind to HP. Sequence alignment of alpha chains of collagens V and XI indicated that these two collagen types may use a common sequence motif to interact with heparin. This hypothesis was confirmed experimentally by others (9). The recombinant production of HepV in E. coli has set the stage for identifying the heparin-binding site by site-directed mutagenesis and affinity chromatography. We have previously identified within the Lys 905 -Arg 921 sequence of the α1(V) chain five basic residues participating in the binding of HepV to heparin (10), but the molecular features of heparin responsible for the specific recognition of HepV have not been characterized, although the characteristics of heparin/heparan sulfateprotein interactions have been elucidated for several other proteins (for reviews see 11, 12). Furthermore, previous studies were performed with heparin, a chemical analog of heparan sulfate (HS), but not with HS. However, HS, which is ubiquitously distributed on the surface of cells and in the extracellular matrix, is the physiological glycosaminoglycan ligand of collagen V, and a number of biological roles have been reported for HS through its interaction with extracellular matrix proteins (for reviews see 13, 14). In our first studies (8, 10), the affinity of the binding of HepV and its mutants to heparin was qualitatively evaluated by affinity chromatography using heparin-Sepharose. HepV and its mutants were eluted with sodium chloride, the concentration of which was taken as an estimate of the binding affinity. However, this commonlyused technique measured only the ionic component, the most prominent interaction between heparin and a protein, but failed to measure the hydrophobic and hydrogenbonding contribution to the binding (11).
Proteoglycans
are widely distributed at the cell surface and in the extracellular matrix. They consist of a protein core to which one or more glycosaminoglycan side chains are covalently attached conferring a strong negative charge on proteoglycans (1, 2) . Interactions of proteoglycans with a number of matrix proteins including collagens are important in regulating cell behaviour and fibril formation during development and pathophysiological events. Interactions with collagens can be dependent on the proteoglycan core protein or on the glycosaminoglycans chains. The heparan sulfate chain has various important biological properties and influences cell behavior through interactions with a variety of matrix proteins. Heparin-binding sites have been identified and characterized in a wide range of matrix proteins including collagens, but the structural requirements for heparan sulfate to bind these proteins is not fully understood.
Collagen V, although a quantitatively minor component of connective tissues plays a crucial role in matrix organization. Several isoforms of collagen V, including hybrid molecules containing collagen XI chains (3), occur in tissues, but the predominant molecular form is the heterotrimer [α1(V)] 2 α2(V), whereas the α1(V)α2(V) α3(V) molecule and the [α1(V)] 3 homotrimer are minor isoforms with a more restricted tissue distribution. Collagen V interacts with proteoglycans, which are widely distributed at the cell surface and in the extracellular matrix. It binds to the two small proteoglycans, decorin and biglycan, to the proteoglycan form of macrophage colony-stimulating factor (4) , to the membrane chondroitin sulfate proteoglycan NG2 (5) and to syndecan-1 (6, 7) . Binding to collagen V involves either the core protein or the glycosaminoglycan chains. Collagen V was shown to bind heparin (HP) through a 12kDa fragment of the α1(V) chain referred to as HepV. Interestingly, we also showed that the recombinant HepV fragment supports heparin-dependent cell adhesion (8) . The binding site for heparin is found in the α1 chain of collagen V, whilst the two other chains of collagen V, α2(V) and α3(V), do not bind to HP. Sequence alignment of alpha chains of collagens V and XI indicated that these two collagen types may use a common sequence motif to interact with heparin. This hypothesis was confirmed experimentally by others (9) . The recombinant production of HepV in E. coli has set the stage for identifying the heparin-binding site by site-directed mutagenesis and affinity chromatography. We have previously identified within the Lys 905 -Arg 921 sequence of the α1(V) chain five basic residues participating in the binding of HepV to heparin (10) , but the molecular features of heparin responsible for the specific recognition of HepV have not been characterized, although the characteristics of heparin/heparan sulfateprotein interactions have been elucidated for several other proteins (for reviews see 11, 12) . Furthermore, previous studies were performed with heparin, a chemical analog of heparan sulfate (HS), but not with HS. However, HS, which is ubiquitously distributed on the surface of cells and in the extracellular matrix, is the physiological glycosaminoglycan ligand of collagen V, and a number of biological roles have been reported for HS through its interaction with extracellular matrix proteins (for reviews see 13, 14) . In our first studies (8, 10) , the affinity of the binding of HepV and its mutants to heparin was qualitatively evaluated by affinity chromatography using heparin-Sepharose. HepV and its mutants were eluted with sodium chloride, the concentration of which was taken as an estimate of the binding affinity. However, this commonlyused technique measured only the ionic component, the most prominent interaction between heparin and a protein, but failed to measure the hydrophobic and hydrogenbonding contribution to the binding (11) .
In this study, we further characterized the interactions between collagen V and heparin by surface plasmon resonance (SPR) assays i) to take into account the whole set of non-covalent interactions participating in the interactions, ii) to study the influence of divalent cations, and iii) to measure rate constants and to calculate the affinity constant governing those interactions by kinetic analysis. The amino acids crucial for the binding of HepV to heparin/heparan sulfate and to cells were precisely mapped within the heparin-binding site. We also determined the chemical structures of the glycosaminoglycan chains (size, sulfate substitution pattern) required for binding, because subtle changes in heparan sulfate structure, and especially the fine structure of heparan sulfate with specific monosaccharide sequences characterized by the sulfation pattern (11, 12, (15) (16) (17) , can modulate HS-binding and proteoglycan activity (18) . Those experiments were carried out using the monomeric, nontriple-helical fragment HepV, and fulllength, triple-helical isoforms of collagen V, namely the [α1(V)] 2 α2 heterotrimer and the [α1(V)] 3 homotrimer. The dependence of the interaction between collagen V and heparin/heparan sulfate upon the triple-helical conformation of collagen V was also investigated with a triple-helical synthetic peptide containing the fifteen amino acid residues of the previously-defined heparin binding site (10) . Taken altogether, these results emphasize differences between the binding of the HepV fragment and of the fulllength collagen V molecules to heparan sulfate. This suggests that a different network of interactions between collagen V molecules and HepV with their respective glycosaminoglycan ligands may modulate biological functions in vivo during remodeling of the extracellular matrix for HepV or in the organization and assembly of extracellular matrix for the collagen V isoforms.
Experimental Procedures
Construction, expression and purification of HepV and its mutants -The recombinant HepV fragment and mutant constructs were prepared as previously described and inserted into the EcoRI and Pst1I sites of the pT7/7 expression vector (8, 10) . The recombinant wild type plasmid named pHepV and the mutants named after the mutation, e.g. pR909A and R909A were transformed in an E. Coli strain (BL21 SI -GJ1158) that carries the T7 RNA polymerase gene under the control of the lac promoter/operator and that makes use of NaCl as an inducer (19) . Cells were harvested by centrifugation 6 after 0.2 M NaCl induction, resuspended in 50 mM Tris/HCl, pH 7.4 and then sonicated. After centrifugation and filtration, bacterial supernatants were first subjected to cationexchange chromatography using a
HiTrapSP column (Pharmacia, Biotech) to remove most contaminant bacterial proteins and were purified to homogeneity using a monoQ column (Pharmacia, Biotech) as previously described (8 referred to HepP was prepared using methodology previously described (8) . The corresponding triple-helical peptide, G904-R918, GPC-(GPP)5-GKOGPRGQRGPTGPR-(GPP)5-GPC-NH 2, was prepared as previously described, and its triple-helical state was checked by polarimetry (22 (26) . Ligand Blotting -Calcium binding was studied by ligand blotting and 45 Ca autoradiography (23) using a nitrocellulose membrane (Schleicher and Schuëll). Different concentrations of purified proteins were applied on the membrane using a dot-blot apparatus. Each well was washed twice (2 x 200 µl) with 10 mM imidazole buffer pH 6.8 containing 60 mM KCl and 5 mM MgCl 2 . Membranes were incubated with 45 CaCl 2 (Amersham Biosciences) at a final concentration of 2 µCi/ml for 15 min, rinsed with 50% ethanol for 5 min, dried, and exposed overnight to a BioMax MS film in a cassette with an intensifying screen. The C-terminal propeptide of procollagen III (gift from D. Hulmes, Institut de Biologie et Chimie des Protéines, Lyon, France) was used as a positive control (23) .
Circular dichroism (CD) spectroscopy -
The CD spectra were recorded on a Jasco J-800 dichrograph. HepV (5 µM) was dialyzed against 10 mM potassium phosphate buffer pH8. Glycosaminoglycans were either added to HepV prior to analysis or incubated overnight with HepV at 4°C with gentle mixing before recording the CD spectra. Spectra were collected from 190 nm to 260 nm with a step size of 1 nm and a bandwidth of 1 nm at 20°C. They were corrected for buffer baseline measured in the same cells of path length 0.1 cm. Five spectra of each sample were averaged. The circular dichroism signal of heparin and heparan sulfate was also subtracted to determine genuine changes in HepV conformation. The results were normalized to mean molar residue ellipticities. Cell adhesion assays -Chinese Hamster Ovary (CHO) cells were maintained in monolayer cultures in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, glutamine, nonessential amino-acids and a cocktail of antibiotics. Prior to the adhesion assay, cells were harvested with 1% EDTA in phosphate-buffered saline (PBS) pH 7.4. 96-well plates (Costar, France) were coated overnight at 4 °C with HepV and mutants with 1 µg per well. After blocking the wells with 1% bovine serum albumin (BSA), cells freshly suspended in serum free medium (5 x 10 5 cells/ml) were plated onto wells (0.1 ml/ well), and allowed to attach for 45 min at 37°C. Then, the wells were gently washed with PBS, fixed with 1% glutaraldehyde and stained with 0.1% crystal violet. After extensive washing, the dye adsorbed to the cells was solubilized in 0.2% Triton X-100 and the absorbance was read at 570 nm with an ELISA plate reader (SLT Lab Instrument, Austria). Cell adhesion experiments were performed three times, each assay point being carried out in duplicate.
RESULTS

HepV binds to heparin and heparan sulfate with a high affinity
The expression of the wild-type HepV fragment and its mutants was markedly increased (by up to 20-fold) using the BL21 SI E. Coli strain that used NaCl as an inducer. Hep V ( Figure 1A ) and mutants were efficiently purified by successive anion-and cation-exchange chromatography steps. The binding of HepV to heparin and heparan sulfate was inhibited in a dosedependent manner by heparin and heparan sulfate (Table 1) in SPR inhibition assays, thus assessing the specificity of the binding. Kinetic analysis of those interactions was performed by injecting different concentrations of HepV over immobilized heparin ( Figure 1B ) and heparan sulfate to determine the affinity constant K D, which was calculated as the ratio of the rate constants k a /k d using the BIAevaluation software. (Figure 2A ). Contrary to our previous results (10), the binding level of K905A and R909A mutants to heparin/heparan sulfate was significantly reduced, indicating that these two residues are also essential for HepV binding to heparan sulfate. Those two particular residues were also critical for CHO cell adhesion to HepV, whereas R912A and R918A, but not R921A, mutants decreased CHO cell adhesion to HepV ( Figure 2B 
A decasaccharide of heparan sulfate is required for HepV binding
The minimum size of heparin and heparan sulfate required for HepV binding was evaluated by performing SPR inhibition assays with heparin and heparan sulfate oligosaccharides of defined size. Heparin (dp2-18, where dp represents the degree of polymerization) and heparan sulfate (dp4-18) oligosaccharides were screened to examine their ability to compete with immobilized heparin or heparan sulfate for binding to HepV. The smallest size of heparin inhibiting at least 50% of HepV binding to heparin was an octasaccharide ( Figure  5A ), whereas a longer oligosaccharide of heparan sulfate (a decasaccharide) was required to achieve a similar level of inhibition ( Figure 5B ). No significant inhibition was observed with heparan sulfate tetrasaccharide and hexasaccharide, whereas a heparin hexasaccharide inhibited the binding of HepV to heparin and heparan sulfate by 42.7% and 55.9% respectively.
2-O sulfation of heparin strongly contributes to the binding of HepV
Inhibition experiments were carried out with selectively desulfated heparins (26) . to identify the sulfate groups of heparin involved in HepV interaction. Desulfated heparins were incubated for 1 h with HepV before injection onto immobilized heparin or heparan sulfate. If a particular desulfated heparin retains the capacity to interact with HepV, the injection of the complex will result in inhibition of HepV binding to the immobilized glycosaminoglycans. Hence, strong inhibition by a modified heparin indicates that the (removed) sulfate groups did not prevent the binding of modified heparin to HepV during the preincubation step and consequently, that they are not involved in HepV recognition. Selectively 2-O desulfated heparin did not inhibit the binding of HepV to heparin or heparan sulfate indicating that 2-O-sulfation was required for heparin binding to HepV (Table 3) . N-desulfation inhibited the binding of HepV to heparin and heparan sulfate by 30 and 40% respectively, whereas the removal of 6-O sulfate impaired 50% and 60% of the binding to heparin and heparan sulfate respectively (Table 3) . 2-O-sulfation contributed the most to the binding of HepV, whereas Nand 6-O-sulfation participated to a lesser extent.
No significant structural change is induced in HepV upon its binding to heparin and heparan sulfate
To determine whether structural changes could be induced in HepV by its binding of heparin and heparan sulfate, HepV was analyzed by circular dichroism spectroscopy with and without added glycosaminoglycans. The CD signals exhibited a minimum at 198-200 nm (data not shown). A typical spectrum of triplehelical collagen exhibited a minimum at 195-200 nm and a maximum at 220-223 nm. No maximum was observed on the CD spectrum of HepV (data not shown) suggesting that this fragment did not adopt a triple helical conformation. We reported previously that HepV can fold into a triple helical structure after in vitro renaturation at high concentration (1 mg/ml) using an annealing procedure (32) . However, as shown by our circular dichroism data, HepV does not fold spontaneously into a triple-helical conformation at the concentration used for our experiments.
No significant change in molar ellipticity of HepV was observed at the minimum either when the spectra were recorded 15 min after addition of glycosaminoglycans at 5, 25 and 50 µM or when the spectra were recorded after overnight incubation at 4°C with several concentrations of heparan sulfate (heparan sulfate/HepV molar ratios: 1:1, 5:1 and 10:1). Indeed, changes in molar ellipticities were limited to 7% for the samples analyzed 15 min after glycosaminoglycan addition and to 4.5% for the samples incubated overnight. This suggests that heparin or heparan sulfate did not induce significant changes in HepV conformation upon binding.
The collagen V homotrimer and heterotrimer form very stable complexes with heparin and heparan sulfate
Recombinant collagen V homotrimer, which comprised three α1 chains, and heterotrimer both bound to heparin and heparan sulfate to a higher extent than HepV. The highest binding level, measured in resonance units, was obtained for the heterotrimer (Figure 6 ). Collagen V heterotrimer bound to heparin and heparan sulfate with a higher affinity (K D ~ 5.62 nM and 2.0 nM respectively, 1:1 Langmuir model) than HepV. Collagen V homotrimer formed more stable complexes with heparan sulfate than HepV as demonstrated by a lower dissociation rate on the sensorgram (Figure 6 ). This extremely low dissociation rate prevented the calculation of reliable kinetic constants using the BIAevaluation software and thus of the affinity constant. Heat denaturation of the homotrimer for 15 min at 100°C decreased its binding to heparin by 71% indicating that the triple helix conformation participated in its recognition. Collagen I, which is known to bind heparin through a basic triple helical domain (7), exhibited an intermediate binding level between the two forms of collagen V. It binds to heparin and heparan sulfate with a similar affinity (K D ~3.4 nM and 3.5 nM respectively). Our results show that collagen I and collagen V heterotrimer exhibit similar affinities. It has been previously reported that collagen I has a lower apparent affinity for heparin/heparan sulfate than collagen V as determined by solid phase assays (33) and by affinity co-electrophoresis (34) . This discrepancy is likely due to difference in the experimental procedure and in collagen sources.
Molecular characterization of the interaction of the collagen V homotrimer with heparin
The specificity of the binding of the collagen V homotrimer to heparin/heparan sulfate was assessed by SPR inhibition experiments. Heparin inhibited the binding of HepV to heparin and to heparan sulfate (Table 4) . A higher concentration of heparan was required to achieve inhibition levels similar to those obtained with heparin ( Table 4 ). The minimal size of heparin that promoted a significant binding of the homotrimer to heparin was found to be a decasaccharide by SPR inhibition assays ( Figure 7) . SPR inhibition experiments were also performed with modified heparins as described above for HepV. De-N-sulfated and re-N-acetylated heparin did not inhibit the homotrimer binding to glycosaminoglycans, suggesting that N-sulfation of heparin was crucial for the binding, whereas 2-O and 6-O sulfation contributed to the binding to a lower extent (Table 5 ).
DISCUSSION
The investigation of the functional relevance of glycosaminoglycan-collagen V interactions required first their characterization at the molecular level. The identification and characterization of the heparin binding site of the α1(V) chain demonstrated that trimeric collagen V molecules and a monomeric recombinant fragment, referred to as HepV, bind efficiently to heparin and heparan sulfate through a common motif containing a cluster of 5 basic residues, which was identified by site-directed mutagenesis (8, 10) . The binding of HepV and its mutants to heparin was assessed by affinity chromatography on heparin-sepharose and the relative strength of the binding was determined by the salt concentration required to elute them from the resin (10 and Arg 909 in the binding of the HepV fragment to heparin/heparan sulfate and to the cells. This discrepancy between the affinity chromatography assays and the SPR experiments might be due to the fact that heparin-sepharose acts as a cationexchanger because of the highly negative charge of heparin. In this approach, the amount of salt required for elution of HepV and its mutants from the affinity column is a quantitative measure of the ionic component of the binding, but this technique fails to measure the hydrophobic and hydrogen-bonding contributions to binding (11) , whereas SPR assays take into account all the possible bonding mechanisms. Furthermore, deviations between the relative ionic strength elution of proteins from heparin-sepharose and direct affinity measurements have been observed (17) , suggesting that differential ionic strength elution of HepV and its mutants may not reflect their true relative affinities.
In addition, similar results were obtained by assessing CHO cell has not yet been determined but, from our previous data, it is unlikely that it binds to collagen V through the heparin binding site since we previously showed that (i) heparan sulfate, but not chondroitin sulfate, efficiently inhibits heparin binding to HepV, and (ii) CHO cell attachment to HepV is inhibited by heparin and heparan sulfate but not by chondroitin sulfate (8) . Collagen V is a fibrillar collagen that generally copolymerizes with collagen I to form heterotypic fibrils. However, it has also the property of forming fibrils that show a preferential pericellular localization (8) . Since collagen V can interact with cells through its heparin binding site and is located pericellularly (8) , heparan sulfate proteoglycans associated with the cell surface, such as syndecans and glypicans or to the basement membrane such as perlecan are likely good candidates for collagen V binding partners.
HepV binds to heparin and heparan sulfate with a lower affinity (K D ~ 18 and 36 nM respectively) than the collagen V heterotrimer (K D ~ 5.6 and 2.0 nM respectively). This does not mean that HepV binding to heparin is not physiologically relevant. Hep V might be generated by proteolytic cleavage of collagen V in physio-pathological situations where extensive extracellular matrix remodeling occurs, whereas interactions between heparan sulfate and native collagen molecules could play a role in the cohesion and assembly of the extracellular matrix. Moreover, we showed previously (8) , and in the present report, that HepV can promote cell adhesion.
Triple-helical molecules such as the GPC(GPP) 5 G 904 -R 918 (GPP) 5 GPC-NH 2 peptide and the homotrimeric and heterotrimeric collagen V molecules form very stable complexes with heparin and heparan sulfate. The extremely slow dissociation rate of the corresponding complexes observed in SPR assays demonstrates that the triple helix strongly stabilizes the complexes formed between the triple helical peptide, or native, triplehelical collagen V molecules, and the glycosaminoglycans. The increased level in binding of triple helical peptides and of collagen molecules to heparin/heparan sulfate might be due to the association of three identical (homotrimer) or different (heterotrimer) α chains into a triple helix that can generate new combinations of basic amino acid residues. This could modify the affinity for heparin by clustering a higher number of basic amino acid residues. Concerning the heterotrimer, the triple helix formation could reinforce the efficiency of heparin binding by contributing basic aminoacids of the α 2 (V) sequence. Two arginine residues of the α 2 (V) chain can contribute to the heparin binding site because they are in close proximity with the basic amino acid K905 and R912 of the α 1 (V) chain, as shown in our previously established molecular model (8) . The affinity of glycosaminoglycan-collagen V inter-actions in tissues might be modulated in function of the collagen V chain associations, [α1(V)] 2 α2(V), [α1(V)] 3 and α1(V)α2(V)α3(V) as previously suggested (8) . Besides difference in binding affinities, we also showed distinct structural requirement for heparin/heparan sulfate binding to HepV and collagen V molecules. This strengthens the idea that collagen V and HepV may interact with distinct sequences of glycosaminoglycans in the extracellular matrix or at the cell surface. The minimal size of heparin required for efficient binding of HepV and of the homotrimer to heparin was an octasaccharide and a decasaccharide respectively. Heparin forms a right-handed helix and successive disaccharide units in the heparin chain are related by a rotation of about 180° and a translation of 0.8-0.87 nm (38) . This leads to a length ranging between 3.2 and 3.5 nm for a heparin octasaccharide and between 4.0 and 4.35 nm for a decasaccharide. A decasaccharide was the smallest heparan sulfate oligosaccharide able to bind significantly to HepV. Given that heparan sulfate chains adopt an extended helical coil in solution, with a disaccharide unit length of approximately 0.75 nm (39) , the length of a heparan sulfate decasaccharide is about 3.75 nm. In all cases, the minimal length of glycosaminoglycan required for HepV or collagen V binding to heparin/heparan sulfate is shorter than the distance separating the two extreme amino acid residues of the heparin binding site Lys 905 and Arg
921
, which has been evaluated as 4.5 nm (8) .
Although it is difficult to attribute a biological function to a specific sulfation motif of heparan sulfate, the sulfation pattern can modulate its biological activity and its binding to proteins (11, 12, 17) . 2-O-sulfation of heparin, which occurs at the C-2 position of the uronic acid residues, is critical for HepV binding and 6-Osulfation of glucosamine residues significantly contribute to the binding. In contrast, the contribution of 2-0 and 6-O sulfation to the binding of the triple helical collagen V homotrimer was low, whereas N sulfate groups played a prominent role. The distinct sulfation preferences of HepV and of the homotrimer suggest that they did not bind to the same residues on heparin and indicate that different sulfation motifs carry instructions for protein binding. Information in the form of a sulfation code could be a means of molecular-level control as suggested by Habuchi et al. (16) . It should also be noted that we characterized interactions in terms of the sulfate groups required but not in terms of the conformation adopted by each glycosaminoglycan sequence, and it has been suggested that substitution pattern may influence the conformation around the glycosidic linkages (17) . Furthermore, the homotrimer has a triple-helical conformation, whereas HepV does not, as demonstrated by circular dichroism, and that might contribute to their different requirements for sulfate group binding. It has been previously reported for the heparin binding domains of the acetylcholinesterase collagen tail that addition of increased amounts of heparin can increase the triple-helix content and the thermal stability of triple-helical peptide models (40, 41) . However, addition of heparin and heparan sulfate at different concentrations failed to induce significant structural change in HepV even during an overnight incubation.
A number of proteinglycosaminoglycan interactions have been reported to involve cations. The interaction of endostatin (24) and heparin cofactor II (31) with heparin/heparan sulfate depend upon zinc. The interaction of fibroblast growth factor receptor with heparin requires divalent cations at levels present in extracellular fluids (29) , and copper bridges promote a tighter interaction of prion protein with heparin and heparan sulfate (29) . We showed in this study that the binding of HepV to heparin/heparan sulfate is also cation-dependent and involved Ca 2+ SPR inhibition experiments. The homotrimer of collagen V (20 µg/ml) was preincubated with heparin oligosaccharides of different size (dp: degree of polymerisation) for 1 h at room temperature before its injection over immobilized heparin () and heparan sulfate (). Results were expressed as percentage of inhibition of the binding in the absence of competing oligosaccharides. Table 5 : SPR inhibition experiments. The homotrimer of collagen V (20 µg/ml) was preincubated with modified heparins (0.7 µg/ml) for 1 h at room temperature before its injection over heparin and heparan sulfate immobilized on the sensor chip. The results were expressed as percentage of inhibition of the binding in absence of modified heparins.
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